Overexpression of CIP2A is associated with poor prognosis in multiple myeloma

• DOI: 10.1038/sigtrans.2017.13
• Publication Date: 2017-05-26T06:23:10Z
• Authors: Xuewen Liu; Wei Cao; Shanshan Qin; Te Zhang; Junnian Zheng; Ying Dong; Pinghong Ming; Qian Cheng; Zheng Lu; Yang Guo; Baofu Zhang; Ying Liu
• Keywords: Tumor progression

Abstract Cancerous inhibitor of protein phosphatase 2A (CIP2A), an endogenous (PP2A) inhibitor, has been identified as oncoprotein in promoting cancer initiation and progression several types cancer. However, the expression role played by CIP2A pathogenesis multiple myeloma (MM) remain unclear. In this study, we showed that was overexpressed human MM cell lines patients’ bone marrow tissues. Clinicopathologic analysis significantly correlated with clinical stage percent plasma cells marrow. Kaplan–Meier revealed patients high presented poorer overall survival rates than those low expression. Moreover, knockdown resulted attenuated proliferative abilities. addition, depletion sensitizes dexamethasone (Dex)-resistant to Dex. The effect on proliferation Dex therapy mediated inhibition PP2A, which turn activated Akt. vivo studies confirmed regulated tumorigenesis phosphorylation Taken together, our results suggest plays important could serve a prognosis marker novel therapeutic target for treatment MM.